Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-06-12
Item 5.02
The disclosure centers on the appointment of Robert Stefani as Manager, Secretary and Treasurer of Empire District Bondco, LLC effective June 10, 2026. While Fraser McNamee's departure is also mentioned, the substantive focus is on Stefani's appointment to the executive role, with detailed background on his prior experience as CFO at Algonquin (the indirect parent), Southwest Gas Holdings, and PECO Energy. The appointment of a new manager and treasurer to a company is material to investors assessing the registrant's governance and leadership.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-06-12
EX-99.1
The exhibit announces completion of a multi-part debt financing transaction: repayment of €62.2 million in EIB Loans, issuance of €35 million in Tranche A Convertible Bonds, and €40 million in Tranche B Amortized Bonds (€75 million aggregate), plus issuance of Lenders' Warrants. While the exhibit also covers warrant repurchase and equity offering, the primary disclosed action is the creation of new direct financial obligations (convertible and amortized bonds) with BlackRock and Claret Capital Partners, which is the core debt_issuance event. The transaction materially affects the registrant's capital structure and financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Lument Finance Trust, Inc. held its annual meeting of shareholders on June 10, 2026, with voting results on three matters: re-election of six directors, advisory approval of named executive officer compensation, and ratification of KPMG, LLP as independent auditor. Detailed vote tallies including shares for, against, withheld, abstentions, and broker non-votes are disclosed for each proposal.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
Item 7.01
Lument Finance Trust, Inc. declared cash dividends of $0.04 per share on common stock and $0.4921875 per share on Series A Preferred Stock. These dividend declarations represent a material capital allocation decision affecting shareholder returns.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual General Meeting held on June 12, 2026, covering three proposals: election of six directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches Item 5.07 requirements and presents tabulated voting outcomes for each matter.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-12
Item 8.01
American Homes 4 Rent entered into an at-the-market (ATM) offering program on June 12, 2026, authorizing the sale of up to $1.0 billion in Class A common shares through multiple sales agents and forward sellers. The disclosure explicitly describes the mechanics of an ATM offering under Rule 415 of the Securities Act, including forward sale agreements that allow the company to borrow and sell shares before physical settlement. This is a material dilutive issuance that would affect shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 8.01
Amazon closed a C$13.967 billion debt offering across five tranches of senior notes maturing 2029–2056, with net proceeds of approximately C$13.934 billion, affecting the company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
SmartKem, Inc. disclosed that its wholly owned subsidiary, SmartKem, Ltd. (a UK corporation), is being placed into creditors' voluntary liquidation. While the parent company states it has not filed for bankruptcy and continues operations, the liquidation of a wholly owned subsidiary is a material corporate event affecting the registrant's asset base and organizational structure. The disclosure does not fit neatly into bankruptcy_filing (the parent is not filing) or going_concern (no doubt about the parent's continuity is expressed), making other_material the most appropriate classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-12
EX-99.1
The exhibit discloses Lotus Tech's advancement of a strategic acquisition of Lotus UK expected to close in 2026, described as an "acquisition under common control" that will unify brand positioning and improve operational efficiency. The company is conducting comprehensive regulatory, SOX compliance, and integration planning. This constitutes material M&A activity under Item 1.01 / 2.01 equivalent disclosure. The temporary suspension of Q1 and Q3 earnings releases is a secondary operational consequence of prioritizing acquisition-related compliance work, not the primary event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
International Seaways held its Annual Meeting of Stockholders on June 8, 2026, with voting results disclosed on four matters: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and ratification of a Rights Agreement. Detailed vote tallies for each director nominee and resolution are provided.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-12
Item 5.02
The Board approved material compensatory arrangements for named executives and directors, including base salary increases retroactive to January 1, 2026 for the CEO, CFO, CAO, Controller, and other senior officers, as well as increases to annual equity target opportunities ranging from 75% to 400% of base salary and equity compensation for non-employee directors.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 7.01
The filing discloses deferral of a Phase 2a clinical trial for tivoxavir marboxil due to a negative regulatory review by the UK's Medicines and Healthcare Products Regulatory Agency. This represents a material setback to a key drug development program that would affect investor assessment of the company's pipeline and prospects, but does not fit neatly into the more specific event categories (it is neither a restatement, impairment charge, litigation, nor M&A activity). The regulatory rejection of a planned clinical study is a material development for a pharmaceutical company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
Item 2.01
Rocket Pharmaceuticals completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $180.0 million gross proceeds on June 10, 2026, pursuant to an asset purchase agreement dated April 26, 2026. This material asset disposition represents a significant one-time cash inflow affecting the company's liquidity and financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
Item 5.07
UniFirst shareholders voted on June 11, 2026 to approve a merger agreement with Cintas Corporation, with the Merger Agreement Proposal receiving 47,458,203 votes in favor, 10,251 against, and 17,219 abstentions. A non-binding compensation proposal was also approved. The filing discloses these voting results via Item 5.07 and a press release furnished under Item 7.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
Item 8.01
UniFirst disclosed an update on its material merger with Cintas Corporation, originally entered into on March 10, 2026, whereby UniFirst will be merged into Cintas subsidiaries in a two-step transaction. The FTC issued a Second Request on June 11, 2026, extending the HSR Act waiting period and affecting the timeline for transaction completion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-12
Item 8.01
The disclosure describes a material acquisition transaction: Helix Energy Solutions Group, Inc. (Parent) is merging with Hornbeck Offshore Services, Inc. through a two-step merger structure. The filing reports that the FTC granted early termination of the Hart-Scott-Rodino waiting period on June 11, 2026, a key regulatory milestone. The transaction is expected to close in the second half of 2026, subject to shareholder approval and remaining regulatory approvals. This constitutes a material M&A activity requiring 8-K disclosure under Item 1.01 or 2.01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Cherry Hill Mortgage's June 11, 2026 annual meeting. The filing reports detailed vote tallies for four matters: re-election of five directors, advisory approval of named executive officer compensation, ratification of EY as auditors, and a charter amendment proposal. The disclosure of voting outcomes on material corporate governance matters is a standard and material event for investors assessing board composition and shareholder sentiment.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
Ionis disclosed positive clinical trial data from the CORE-OLE extension study of olezarsen, including longer-term hepatic MRI-PDFF results showing mean HFF levels returning toward baseline after 24 months of treatment and continued favorable safety profile. While this is a clinical update rather than a traditional material event category (earnings, M&A, restatement, etc.), the disclosure of significant trial results for a late-stage drug candidate would materially affect investor assessment of the company's pipeline and commercial prospects, particularly given the high patient retention rate (>90%) and the focus on a severe indication (sHTG).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
Item 8.01
This 8-K Item 8.01 discloses supplemental proxy statement disclosures in connection with a previously announced merger agreement between AES Corporation and Horizon Parent, L.P. (dated March 1, 2026). The filing addresses stockholder litigation and demand letters challenging proxy disclosures, and provides supplemental information regarding financial advisor conflicts and valuation analyses. While technically filed under Item 8.01 (Other Events), the substance centers on the material acquisition transaction and related proxy disclosure updates required to facilitate the stockholder vote scheduled for June 26, 2026.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-06-12
EX-99.1
ING announced a partial reduction of its stake in TMBThanachart Bank from 23.1% to 19.5%, generating approximately €243 million in gross proceeds through participation in TTB's share buyback programme. This is a material divestiture or asset sale—a financial event involving the reduction of a significant equity investment. While the press release states the transaction is "not expected to have a material impact on ING's profit and loss account," the €243 million proceeds and the strategic shift in portfolio composition (reducing a major shareholding) are material to investors assessing ING's capital allocation and investment portfolio. This does not fit the specific categories of M&A activity, debt issuance, or dividend distribution, so financial_other is the appropriate classification.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-12
The 6-K discloses a warrant inducement agreement dated June 12, 2026, whereby Rubico Inc. induced existing Class C warrant holders to exercise warrants at a reduced price ($0.95 to $0.65 per share), generating approximately $4.8 million in net proceeds. In exchange, the exercising holders receive new Class D Warrants to purchase up to 15,789,480 common shares in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance—the company is issuing unregistered warrants (and the underlying common shares upon exercise) to raise capital, which will dilute existing shareholders' ownership and voting power. The filing explicitly discusses dilution risks and notes that as of the filing date, there will be 15,670,898 common shares outstanding plus substantial additional shares issuable under various warrants and convertible securities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This 8-K Item 5.07 discloses the results of Corvus Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 11, 2026, including tabulated votes on three proposals: election of Class I directors (Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and a non-binding advisory vote on named executive officer compensation. The disclosure provides vote counts (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
BioCryst Pharmaceuticals held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four matters: election of three directors (Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse), ratification of Ernst & Young LLP as independent auditors, an advisory vote on executive compensation, and approval of an amended and restated Stock Incentive Plan increasing available shares by 7,000,000 shares. All proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-12
EX-99.1
XORTX announces a voluntary election to delist its common shares from the TSX Venture Exchange (TSXV), effective immediately upon Board approval. While this is a voluntary delisting (not a forced delisting due to non-compliance), it represents a material change in the registrant's listing status and trading accessibility for shareholders. The company will maintain its Nasdaq listing, but the removal of the TSXV dual listing affects the total mix of information available to investors regarding trading venues and regulatory obligations. This falls squarely within the delisting_risk taxonomy as a notice of delisting or transfer of listing (Item 3.01 equivalent).
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 92%
filed 2026-06-12
Item 1.01
The filing discloses actual or anticipated defaults under the Company's Credit Agreement and a lender forbearance agreement extending through June 19, 2026. The Company is negotiating an amendment to resolve "concerns related to anticipated or actual defaults," which constitutes a covenant breach or technical default triggering a direct financial obligation. This is a material event indicating financial stress and the need for debt restructuring.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-12
Item 2.02
The filing discloses operating results for the fiscal quarter ended April 30, 2026, with a press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information for a REIT.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-12
Item 2.02
IEH Corporation disclosed its financial results for fiscal year ended March 31, 2026 via press release on June 12, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard annual earnings release disclosure, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
Item 5.07
This is a clear Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on three matters: election of director Lori MacPherson (approved), ratification of BDO USA as auditors (approved), and an advisory vote on named executive officer compensation (not approved). The failed say-on-pay vote is material to investors as it signals shareholder dissatisfaction with executive compensation practices.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-06-12
EX-99.1
This exhibit is the 2026 Incentive Securities Plan adopted by Neo-Concept International Group Holdings Ltd on June 12, 2026. It establishes a comprehensive equity compensation framework allowing the Board to grant options, restricted share units, share appreciation rights, and restricted share awards to employees, directors, consultants, and sub-contractors. The plan reserves 472,856 shares for issuance and sets forth detailed terms for vesting, exercise, and performance criteria. This is a material disclosure of compensatory arrangements that would affect investor assessment of executive and employee incentive structures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
The 8-K discloses Item 5.07 results from Hooker Furnishings' Annual Meeting of Shareholders held June 9, 2026, reporting voting outcomes on three matters: election of seven directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook shareholder vote results disclosure with specific vote tallies for each proposal.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
The filing discloses entry into a $10 million senior secured revolving credit facility with JPMorgan Chase Bank on June 12, 2026 (Item 1.01), with a three-year maturity and financial covenants including a 2.25x total leverage ratio and 1.25x fixed charge coverage ratio. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit cleanly into the standard taxonomy categories—it is neither a debt covenant breach, dilutive equity issuance, nor M&A activity, but rather a routine credit facility arrangement that would be material to investors assessing the registrant's financial position and obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-12
Item 3.02
AmperCap completed an unregistered sale of equity securities, including the partial exercise of an over-allotment option generating $18.375 million in additional gross proceeds and private placement unit purchases by the Sponsor and underwriter representative totaling $551,250, resulting in aggregate capital of $144.8 million placed in trust.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 7.01
Flutter Entertainment disclosed its intention to delist ordinary shares from the London Stock Exchange via RNS announcement on June 12, 2026. This is a material event affecting the registrant's listing status and would significantly impact investors' ability to trade shares on the primary exchange. The disclosure of delisting intention directly triggers Item 3.01 classification (though filed under Item 7.01 as Regulation FD Disclosure).
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-12
EX-99.1
Woodside has exercised a pre-emption right to acquire PetroChina's 10.67% participating interest in the Browse Joint Venture for US$225 million plus contingent payments up to US$175 million, increasing Woodside's equity interest to 41.27%. This is a material acquisition of a significant stake in a major undeveloped gas resource (Australia's largest conventional gas resource with 11.4 million tonnes per annum LNG potential), representing a strategic expansion of Woodside's upstream portfolio and development optionality.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M&A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 8.01
MBX Biosciences announced positive one-year clinical trial data for canvuparatide, its lead therapeutic candidate for chronic hypoparathyroidism, demonstrating a 57% responder rate, favorable pharmacokinetics supporting once-weekly dosing, evidence of physiologic PTH replacement, and a generally well-tolerated safety profile with no new safety signals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear disclosure of shareholder vote results from BioAge Labs' June 10, 2026 Annual Meeting of Stockholders, reporting the election of three Class II Directors (Patrick Enright, James I. Healy, and Rekha Hemrajani) and ratification of KPMG LLP as independent auditor, with detailed vote tallies for each proposal. The filing directly corresponds to Item 5.07 and is material to investors as it documents the composition of the board and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Warner Bros. Discovery's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of thirteen directors, ratification of PricewaterhouseCoopers LLP as auditor, a non-binding say-on-pay vote (which failed), and a sustainability ROI report proposal (which also failed). The failure of the say-on-pay vote is material to investors as it signals stockholder dissatisfaction with executive compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-12
Item 5.02
The filing discloses the appointment of David Justin Haley as Chief Executive Officer of Medallion Bank effective July 1, 2026, succeeding Donald Poulton. While Poulton's retirement as CEO is also mentioned, the principal action disclosed is Haley's appointment to the CEO role. CEO succession is material to investors as it affects leadership and strategic direction of the registrant.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 75%
filed 2026-06-12
Item 8.01
The filing discloses a previously undisclosed event of default with respect to outstanding SBA debentures, which has now been cured by satisfactory completion of background checks. This represents a covenant breach or technical default that triggered a direct financial obligation. The cure of the default is material to investors assessing the registrant's debt compliance and financial stability.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
The Fund discloses preliminary results of a tender offer for share repurchase, with approximately 214,339 shares (0.65% of outstanding) validly tendered. While share repurchases are routine capital allocation activities, this disclosure involves a formal tender offer with material dollar implications and affects shareholder value through NAV per share. The event does not fit neatly into the more specific taxonomy categories (not a dilutive issuance, not M&A, not an earnings release), making "other_material" the most appropriate classification for this shareholder-affecting capital transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes for three proposals: election of four directors (Wayne Burks, Jay Madhu, Peter Politis, and Anthony Saravanos), ratification of Forvis Mazars, LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals were approved by shareholders at the June 10, 2026 annual meeting.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of the Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting results for four proposals: election of three directors (Brandon M. Ribar, J. Chandler Martin, and Sam Levinson), ratification of BDO USA, P.C. as independent auditors, advisory approval of executive compensation, and approval of an amendment to the 2019 Omnibus Stock and Incentive Plan increasing authorized shares from 1,797,600 to 3,197,600. All four proposals were approved by stockholders with detailed vote tallies provided for each.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-12
The 6-K discloses results of an Extraordinary General Meeting held on June 12, 2026, where shareholders voted on and approved two material matters: (1) a share consolidation on a 10-to-30 for 1 basis, and (2) amended and restated articles of association reflecting revised authorized share capital. The filing explicitly states "Three items of business were acted upon by the Company's shareholders at the Adjourned Annual Meeting, each of which was approved by the shareholders" and provides voting tallies (For/Against/Abstain) for each proposal. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent for a foreign private issuer.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Ponce Financial Group held its annual stockholder meeting on June 11, 2026, with shareholders voting on three proposals: election of three directors (Tsavaris, Perez, and Cintron), ratification of Forvis Mazars as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-12
EX-99.1
Sanofi announced its 2026 global employee stock purchase plan (Action 2026), which will issue up to 9.8 million new shares to approximately 75,000 employees across 52 countries at a 20% discount to market price. The issuance represents material dilution to existing shareholders through increased share count and reduced earnings per share.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.2
The European Commission approved Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector for multiple myeloma treatment. This regulatory approval expands the commercial availability and delivery method of the existing marketed drug, representing a material operational and commercial development for Sanofi's oncology portfolio.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
EX-99.3
Sanofi terminated the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. The failure of the phase 3 study represents a material setback to the company's pipeline and R&D direction, affecting investor assessment of future revenue potential.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Item 8.01
Beasley Broadcast Group entered into an Equity Distribution Agreement on June 12, 2026, establishing an at-the-market (ATM) offering program to sell up to $5.2 billion of Class A Common Stock through Noble Capital Markets. This is a classic dilutive equity issuance disclosed under Item 8.01, representing a material capital-raising activity that would affect shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the final certified results of shareholder voting at the June 9, 2026 annual meeting. The filing presents three proposals with vote tallies: election of Class III directors (company nominees prevailed over dissident nominees), ratification of Plante & Moran as independent auditor, and advisory approval of named executive officer compensation. The disclosure is material as it documents shareholder approval of key governance matters including board composition and auditor selection.
View raw filing on EDGAR →